Personalized Medicine Pay Off For Pharma, Payers Contrasted In Study

Private payers may have difficulty realizing a positive short term return on investment for covering a targeted breast cancer therapy like Genentech's Herceptin - at least based on individual patient costs, a study by the Deloitte Center for Health Solutions finds

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet